S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
NASDAQ:MSON

Misonix Stock Forecast, Price & News

$13.94
-0.05 (-0.36 %)
(As of 11/30/2020 04:30 PM ET)
Add
Compare
Today's Range
$13.50
Now: $13.94
$14.11
50-Day Range
$11.35
MA: $12.40
$14.80
52-Week Range
$6.71
Now: $13.94
$20.78
Volume71,531 shs
Average Volume82,642 shs
Market Capitalization$242.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
Misonix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Laboratory apparatus & furniture
Sub-IndustryN/A
Current SymbolNASDAQ:MSON
CUSIPN/A
Phone631-694-9555
Employees254

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.48 million
Book Value$8.45 per share

Profitability

Net Income$-17,420,000.00

Miscellaneous

Market Cap$242.25 million
Next Earnings Date2/3/2021 (Estimated)
OptionableNot Optionable
$13.94
-0.05 (-0.36 %)
(As of 11/30/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MSON News and Ratings via Email

Sign-up to receive the latest news and ratings for MSON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Misonix (NASDAQ:MSON) Frequently Asked Questions

How has Misonix's stock been impacted by COVID-19 (Coronavirus)?

Misonix's stock was trading at $10.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MSON shares have increased by 30.5% and is now trading at $13.94.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Misonix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Misonix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Misonix?

Wall Street analysts have given Misonix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Misonix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Misonix's next earnings date?

Misonix is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Misonix
.

How were Misonix's earnings last quarter?

Misonix, Inc. (NASDAQ:MSON) issued its earnings results on Thursday, November, 5th. The medical equipment provider reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.03. Misonix had a negative net margin of 27.88% and a negative return on equity of 12.44%.
View Misonix's earnings history
.

What guidance has Misonix issued on next quarter's earnings?

Misonix issued an update on its first quarter 2021 Pre-Market earnings guidance on Tuesday, October, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.7-17.7 million, compared to the consensus revenue estimate of $17.07 million.

What price target have analysts set for MSON?

3 equities research analysts have issued 1 year price objectives for Misonix's stock. Their forecasts range from $18.00 to $23.00. On average, they expect Misonix's share price to reach $21.00 in the next year. This suggests a possible upside of 50.6% from the stock's current price.
View analysts' price targets for Misonix
.

Who are some of Misonix's key competitors?

What other stocks do shareholders of Misonix own?

Who are Misonix's key executives?

Misonix's management team includes the following people:
  • Mr. Stavros George Vizirgianakis, CEO & Director (Age 50, Pay $391.84k)
  • Dr. Allan Richard Staley, Pres (Age 60, Pay $364.86k)
  • Mr. Joseph P. Dwyer, CFO, Treasurer & Sec. (Age 64, Pay $347.61k)
  • Ms. Sharon W. Klugewicz, Chief Operating Officer (Age 52)
  • Mr. Robert Scott Ludecker, Sr. VP of Global Sales & Marketing (Age 53)
  • Mr. Linwood A. Staub, Sr. VP of Sales- Wound (Age 58)
  • Dr. Arti B. Masturzo M.D., Chief Medical Officer

What is Misonix's stock symbol?

Misonix trades on the NASDAQ under the ticker symbol "MSON."

Who are Misonix's major shareholders?

Misonix's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.81%), Royce & Associates LP (1.57%), Acuitas Investments LLC (1.32%), Acuitas Investments LLC (1.32%), AWM Investment Company Inc. (1.20%) and State Street Corp (1.06%). Company insiders that own Misonix stock include Joseph J Brennan, Joseph P Dwyer, Sharon W Klugewicz and Stavros G Vizirgianakis.
View institutional ownership trends for Misonix
.

Which institutional investors are selling Misonix stock?

MSON stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, State Street Corp, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, Morgan Stanley, and American International Group Inc..
View insider buying and selling activity for Misonix
.

Which institutional investors are buying Misonix stock?

MSON stock was purchased by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Royce & Associates LP, Essex Investment Management Co. LLC, Acuitas Investments LLC, Acuitas Investments LLC, AWM Investment Company Inc., Raymond James Financial Services Advisors Inc., and Schonfeld Strategic Advisors LLC. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, Sharon W Klugewicz, and Stavros G Vizirgianakis.
View insider buying and selling activity for Misonix
.

How do I buy shares of Misonix?

Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Misonix's stock price today?

One share of MSON stock can currently be purchased for approximately $13.94.

How big of a company is Misonix?

Misonix has a market capitalization of $242.25 million and generates $62.48 million in revenue each year. Misonix employs 254 workers across the globe.

What is Misonix's official website?

The official website for Misonix is www.misonix.com.

How can I contact Misonix?

Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at 631-694-9555.

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.